517. Safety and Tolerability of Intramuscular (IM) Sotrovimab 500 mg Administered at Different Injection Sites: Results from the Phase I COSMIC Study

BACKGROUND: Sotrovimab is a dual-action Fc-engineered human monoclonal antibody (mAb), developed for early treatment of mild-to-moderate COVID-19. We evaluated the safety and tolerability of sotrovimab 500 mg administered intramuscularly (IM) at dorsogluteal (DG), anterolateral (AL) thigh and deltoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Jennifer, Chen, Wen-Hung, Daniluk, Jerzy, Parra, Sergio, Turner, Megan, Sanchez-Pearson, Yasmin, Sakar, Prosenjit, Hawes, Ian A, Aylott, Alicia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678011/
http://dx.doi.org/10.1093/ofid/ofad500.586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678011/
http://dx.doi.org/10.1093/ofid/ofad500.586

Ejemplares similares